Stock Short Interest Filing: Does Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY) Have Gas After Even More Sellers Involved?

November 24, 2016 - By Louis Casey   ·   0 Comments

Stock Short Interest Filing: Does Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY) Have Gas After Even More Sellers Involved?

The stock of Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY) registered an increase of 15.98% in short interest. ALNY’s total short interest was 9.90M shares in November as published by FINRA. Its up 15.98% from 8.54 million shares, reported previously. With 1.42 million shares average volume, it will take short sellers 7 days to cover their ALNY’s short positions. The short interest to Alnylam Pharmaceuticals Incorporated’s float is 16.82%. The stock increased 4.53% or $2.07 on November 23, hitting $47.72. About 1.10 million shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 33.63% since April 22, 2016 and is downtrending. It has underperformed by 39.04% the S&P500.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $3.96 billion. The Firm is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs).

Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.25, from 1.27 in 2016Q1. The ratio fall, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Us Bank & Trust De, a Minnesota-based fund reported 624 shares. First Advisors Limited Partnership last reported 417,247 shares in the company. Rhumbline Advisers holds 0.01% or 80,264 shares in its portfolio. Arrowpoint Asset Management Llc last reported 0.42% of its portfolio in the stock. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Cqs Cayman L P has invested 0.68% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Falcon Edge Capital Limited Partnership holds 2% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 491,713 shares. Principal Gru last reported 0% of its portfolio in the stock. Comerica Bancorporation accumulated 13,714 shares or 0.01% of the stock. Eventide Asset Ltd Company has invested 0.31% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Parametric Limited Liability Company holds 38,077 shares or 0% of its portfolio. Teachers accumulated 0.01% or 63,414 shares. Geode Ltd Llc accumulated 499,616 shares or 0.02% of the stock. California Public Employees Retirement System reported 123,600 shares or 0.01% of all its holdings. Fjarde Ap last reported 0.03% of its portfolio in the stock.

Insider Transactions: Since July 19, 2016, the stock had 1 buy, and 1 insider sale for $918,262 net activity. 27,900 shares were bought by PYOTT DAVID E I, worth $1.03 million on Thursday, October 13. $1.95 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was sold by MARAGANORE JOHN on Tuesday, July 19.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. Alnylam Pharmaceuticals has been the topic of 30 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating given on Thursday, October 6 by Stifel Nicolaus. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The firm earned “Equal-Weight” rating on Thursday, October 6 by Barclays Capital. The rating was maintained by Credit Suisse on Thursday, October 6 with “Outperform”. The firm earned “Overweight” rating on Friday, March 11 by JP Morgan. JP Morgan downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Friday, August 7. JP Morgan has “Neutral” rating and $115 price target. The firm has “Neutral” rating by Janney Capital given on Thursday, September 29. The stock has “Overweight” rating given by JP Morgan on Friday, August 5. Jefferies initiated Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Friday, October 23. Jefferies has “Buy” rating and $107 price target. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Needham on Wednesday, November 16.

ALNY Company Profile

Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.

More recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Why Alnylam Pharmaceuticals, Inc. Took a 47.5% Dive in October” on November 07, 2016. Also Fool.com published the news titled: “Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data” on November 04, 2016. Businesswire.com‘s news article titled: “Alnylam Pharmaceuticals and The Medicines Company Announce Publication of …” with publication date: November 13, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>